NantKwest
ImmunityBio is dedicated to developing innovative immunotherapies that harness the human immune system to fight cancer and infectious diseases. The company collaborates with leading research institutions and conducts clinical trials to bring targeted, personalized treatments to patients worldwide. Their mission is to create therapies that strengthen the immune system, enabling it to outsmart diseases and improve patient outcomes.
Industries
Nr. of Employees
medium (51-250)
NantKwest
Products
Immortalized NK cell reagent for functional assays
An easy-to-maintain, high-cytotoxicity NK cell reagent supplied as a bioanalytical tool to develop reproducible functional killing and ADCC assays as an alternative to donor-derived cells.
GMP-grade off-the-shelf engineered allogeneic NK cell therapy candidates
Clinical-stage allogeneic NK cell therapy candidates produced under GMP conditions, including engineered variants with enhanced direct cytotoxicity, stable high-affinity Fc receptor expression to augment antibody therapies, and CAR-expressing targeted variants.
IL-15–based immunomodulator for combination therapy
A cytokine-based immunomodulatory therapeutic designed to activate NK and T cells, developed for use in combination with antibodies, vaccines, or cell therapies in early-phase clinical trials.
Personalized adenoviral‑vectored neoantigen vaccine platform
A platform combining patient-specific neoantigen selection from integrated genomic, transcriptomic and proteomic profiling with adenoviral vector delivery to prime antigen-presenting cells and induce adaptive anti-tumor immunity.
Immortalized NK cell reagent for functional assays
An easy-to-maintain, high-cytotoxicity NK cell reagent supplied as a bioanalytical tool to develop reproducible functional killing and ADCC assays as an alternative to donor-derived cells.
GMP-grade off-the-shelf engineered allogeneic NK cell therapy candidates
Clinical-stage allogeneic NK cell therapy candidates produced under GMP conditions, including engineered variants with enhanced direct cytotoxicity, stable high-affinity Fc receptor expression to augment antibody therapies, and CAR-expressing targeted variants.
IL-15–based immunomodulator for combination therapy
A cytokine-based immunomodulatory therapeutic designed to activate NK and T cells, developed for use in combination with antibodies, vaccines, or cell therapies in early-phase clinical trials.
Personalized adenoviral‑vectored neoantigen vaccine platform
A platform combining patient-specific neoantigen selection from integrated genomic, transcriptomic and proteomic profiling with adenoviral vector delivery to prime antigen-presenting cells and induce adaptive anti-tumor immunity.
Services
Partnerships and operational support for investigators to test investigational immunotherapies in multi-center clinical studies, including investigator engagement for Phase I/II trials and support for immune monitoring and data analysis.
Facilitation of centralized ethical review and rapid trial start-up for large multi-site clinical networks through partnership with a national IRB providing cloud-enabled review services.
Partnerships and operational support for investigators to test investigational immunotherapies in multi-center clinical studies, including investigator engagement for Phase I/II trials and support for immune monitoring and data analysis.
Facilitation of centralized ethical review and rapid trial start-up for large multi-site clinical networks through partnership with a national IRB providing cloud-enabled review services.
Expertise Areas
- Cell therapy manufacturing and CMC development
- Natural killer cell immunotherapy platforms (engineered and off-the-shelf)
- Neoantigen-based personalized vaccine design
- Integrated multi-omics and bioinformatics for discovery and patient stratification
Key Technologies
- Allogeneic NK cell therapy platforms
- Chimeric antigen receptor (CAR) engineering
- High-affinity Fc receptor expression for ADCC
- IL-15 superagonist cytokine therapeutics
News & Updates
Approximately one in five American adults who had COVID-19 still experience symptoms of long COVID, a serious illness.
Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM).
The Houston medical center became one of the first VA hospitals in the U.S. to provide treatment to a veteran with bladder cancer.
Approximately $43M Sales Following J-Code Impact.
Already approved in the U.S. and designated as a Breakthrough Therapy by the FDA, this marks ANKTIVA’s first marketing approval outside the U.S.
36 months of bladder preservation in over 80% of ANKTIVA® + BCG responders.
Approximately one in five American adults who had COVID-19 still experience symptoms of long COVID, a serious illness.
Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM).
The Houston medical center became one of the first VA hospitals in the U.S. to provide treatment to a veteran with bladder cancer.
Approximately $43M Sales Following J-Code Impact.
Already approved in the U.S. and designated as a Breakthrough Therapy by the FDA, this marks ANKTIVA’s first marketing approval outside the U.S.
36 months of bladder preservation in over 80% of ANKTIVA® + BCG responders.